Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hikma gets rights to commercialize Theravance's Vibativ in the MENA region

Executive Summary

Theravance Inc. (focused on respiratory, infectious, neurological, and GI motility diseases) has licensed Hikma Pharmaceuticals PLC (branded and nonbranded generics) exclusive rights to register, market, and distribute its once-daily injectable antibiotic Vibativ (telavancin) in 16 countries throughout the Middle East and North Africa (MENA) region.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies